Fresenius Medical Care AG (NYSE:FMS) Receives Consensus Rating of “Hold” from Analysts

Shares of Fresenius Medical Care AG (NYSE:FMS) have earned an average rating of “Hold” from the six ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $24.00.

A number of analysts have recently issued reports on FMS shares. Truist Financial increased their price objective on shares of Fresenius Medical Care from $21.00 to $24.00 and gave the stock a “hold” rating in a research note on Wednesday, May 15th. StockNews.com began coverage on shares of Fresenius Medical Care in a research note on Wednesday, July 3rd. They set a “strong-buy” rating for the company.

Hedge Funds Weigh In On Fresenius Medical Care

Several institutional investors have recently bought and sold shares of FMS. Bruce G. Allen Investments LLC purchased a new position in Fresenius Medical Care during the fourth quarter valued at $31,000. Raymond James & Associates grew its stake in shares of Fresenius Medical Care by 4.0% in the 4th quarter. Raymond James & Associates now owns 28,960 shares of the company’s stock worth $603,000 after buying an additional 1,125 shares in the last quarter. Pacer Advisors Inc. grew its stake in shares of Fresenius Medical Care by 14,252.1% in the 4th quarter. Pacer Advisors Inc. now owns 488,401 shares of the company’s stock worth $10,173,000 after buying an additional 484,998 shares in the last quarter. Ritholtz Wealth Management grew its stake in shares of Fresenius Medical Care by 20.1% in the 4th quarter. Ritholtz Wealth Management now owns 30,237 shares of the company’s stock worth $630,000 after buying an additional 5,059 shares in the last quarter. Finally, Uncommon Cents Investing LLC grew its stake in shares of Fresenius Medical Care by 19.7% in the 4th quarter. Uncommon Cents Investing LLC now owns 35,920 shares of the company’s stock worth $748,000 after buying an additional 5,900 shares in the last quarter. 8.25% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Down 0.4 %

FMS opened at $19.61 on Thursday. The firm’s 50 day simple moving average is $20.38 and its two-hundred day simple moving average is $20.04. The company has a current ratio of 1.50, a quick ratio of 1.14 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $11.51 billion, a PE ratio of 22.03, a PEG ratio of 1.05 and a beta of 0.90. Fresenius Medical Care has a 1-year low of $16.37 and a 1-year high of $26.99.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.10. The firm had revenue of $5.13 billion during the quarter, compared to analysts’ expectations of $5.15 billion. Fresenius Medical Care had a net margin of 2.48% and a return on equity of 5.29%. As a group, equities analysts forecast that Fresenius Medical Care will post 1.5 EPS for the current year.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.